Academician Carl H.June
Professor Carl H.June received his MD degree from Baylor College of Medicine in 1979. He is a pioneer in the field of immunotherapy and an academician of the National Academy of Sciences. He is famous all over the world for developing and studying the potential use of adoptive immunotherapy for cancer and HIV infection. He is one of the founders of CAR-T cell therapy. He has served as a professor in the Department of Medicine at the Unified Service University of the American Health Sciences, head of the Department of Naval Medical Research Institute, and chairman of the American Society of Clinical Immunology. He is now a tenured professor at the Perelman School of Medicine of the University of Pennsylvania, the director of the Parker Cancer Immunotherapy Institute (Parker Institute) and the director of the Cellular Immunotherapy Center. In 2011, his research group published new findings detailing a new treatment in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetic engineering of their T cells. This therapy has also been used in the treatment of refractory acute lymphoblastic leukemia in children and refractory lymphoma in adults, and has achieved satisfactory results. CTL019, the first gene therapy method for CAR-T cells developed in Professor's laboratory, was approved by the US FDA in August 2017.
Company address: Floor 4 and Floor 5 (1) of Building 3, Phase 3.1, Wuhan Optics Valley International Biomedical Enterprise Accelerator, 388 Gaoxin 2nd Road, Donghu New Technology Development Zone, Wuhan City
Copyright©2012-2024 Bio-Raid All Rights Reserved Wuhan Porida Biotechnology Co., Ltd. Copyright No. 42018502002564, An Bei, E Public Network